{
    "clinical_study": {
        "@rank": "121265", 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the best way to administer the candidate HIV\n      vaccine, ALVAC HIV-1 (vCP205)."
        }, 
        "brief_title": "HIV Candidate Vaccine, ALVAC-HIV-1, Administration in HIV-Negative Adults", 
        "condition": [
            "HIV Infections", 
            "HIV Seronegativity"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Healthy adult volunteers are assigned randomly to either a vaccine or placebo group.\n      Injections are received either intramuscularly, intradermally, or by delivery under the skin\n      of the volunteer's own white blood cells which have had dendritic cell reinfusion.\n      Volunteers are vaccinated at 0, 1, 3, and 6 month time points. Volunteers are closely\n      monitored for 1 hour after vaccination and keep a diary of symptoms for 1 week\n      post-immunization. Volunteers undergo leukopheresis at the start of the study and after the\n      last vaccination at Walter Reed Army Medical Center. Volunteers receive compensation\n      benefits."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Volunteers may be eligible for this study if they:\n\n          -  Are legal US residents.\n\n          -  Are healthy adults from 18 to 55 years of age.\n\n        Exclusion Criteria\n\n        Volunteers will not be eligible for this study if they:\n\n          -  Are HIV-positive.\n\n          -  Are at highest risk for HIV infection.\n\n          -  Are pregnant or breast-feeding.\n\n          -  Are allergic to eggs or neomycin.\n\n          -  Use certain prescription medications."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "36", 
        "firstreceived_date": "March 21, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00013572", 
            "org_study_id": "B011", 
            "secondary_id": "RV 138"
        }, 
        "intervention": {
            "intervention_name": "ALVAC-HIV MN120TMG (vCP205)", 
            "intervention_type": "Biological"
        }, 
        "keyword": [
            "Injections, Intramuscular", 
            "Injections, Intradermal", 
            "Injections, Subcutaneous", 
            "HIV-1", 
            "AIDS Vaccines", 
            "Dendritic Cells", 
            "HIV Seronegativity", 
            "Genes, env", 
            "Genes, pol", 
            "Genes, gag", 
            "Transfection", 
            "HIV Preventive Vaccine"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rockville", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "20850"
                }, 
                "name": "Walter Reed Army Institute of Research (WRAIR)"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase I Study of Aventis Pasteur Live Recombinant ALVAC-HIV (vCP205, HIV-1 Env/Gag/Pol) in Seronegative Adults Administered (1) Subcutaneously Via Ex Vivo Transfected, Autologous Dendritic Cells, (2) Intradermally, or (3) Intramuscularly", 
        "overall_official": {
            "last_name": "Mary Marovich", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00013572"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Walter Reed Army Institute of Research (WRAIR)", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "study_design": "Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2003"
    }, 
    "geocoordinates": {
        "Walter Reed Army Institute of Research (WRAIR)": "39.084 -77.153"
    }
}